>Each of the above forward-looking statements is subject to change based
on various important factors, including without limitation, competitive
actions in the marketplace and adverse actions of governmental and other
third-party payors. Actual results could differ materially from those
suggested by these forward-looking statements. Further information on
potential factors that could affect LabCorp's financial results is included
in the Company's Form 10- K for the year ended December 31, 2007, and
subsequent SEC filings.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) is a biopharmaceutical
company focused on the development and commercialization of clinical-stage
product candidates for central nervous system disorders. To learn more
about Vanda, please visit http://www.vandapharma.com .
Cautionary Note Regarding Forward-Looking Statements
Various statements in this release are "forward-looking statements"
under the securities laws. Words such as, but not limited to, "believe,"
"expect," "anticipate," "estimate," "intend," "plan," "targets," "likely,"
"will," "would," and "could," and similar expressions or words, identify
forward- looking statements. Forward-looking statements are based upon
current expectations that involve risks, changes in circumstances,
assumptions and uncertainties. Vanda is at an early stage of development
and may not ever have any products that generate significant revenue.
Important factors that could cause actual results to differ materially from
those reflected in the company's forward-looking statements include, among
others: delays in the completion of Vanda's clinical trials; a failure of
Vanda's product c
Page: 1 2 3 4 5 Related biology technology :1
|SOURCE Vanda Pharmaceuticals Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results2
. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference3
. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes4
. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results5
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML6
. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20077
. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results8
. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences9
. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer10
. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences11
. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals